These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 24481271)

  • 1. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
    Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
    Gómez Valbuena I; Alioto D; Serrano Garrote O; Ferrari Piquero JM
    Farm Hosp; 2016 Jan; 40(1):52-4. PubMed ID: 26882834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
    Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
    Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
    Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
    Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review.
    Czarnecka P; Czarnecka K; Tronina O; Durlik M
    Transplant Proc; 2018 Dec; 50(10):4015-4022. PubMed ID: 30577306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
    Kneidinger N; Giessen C; von Wulffen W; Milger K; Schramm R; Jäger G; Nitschko H; Striebinger H; Behr J; Neurohr C
    Int J Infect Dis; 2014 Nov; 28():140-2. PubMed ID: 25267276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
    Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
    John GT; Manivannan J; Chandy S; Peter S; Fleming DH; Chandy SJ; Balakrishnan N; Krishnamurthy K; Kirubakaran MG; Jacob CK
    Transplant Proc; 2005 Dec; 37(10):4303-5. PubMed ID: 16387103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytomegalovirus and kidney transplantation: a clinician's update.
    De Keyzer K; Van Laecke S; Peeters P; Vanholder R
    Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
    Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
    Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
    Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.